CVS Just Turned Its 9,000 Pharmacies Into a GLP-1 Delivery Machine. 1 Top Wall Street Analyst Thinks That's a Reason to Buy the Stock

CVS Health is reframing its sprawling 9,000-store pharmacy footprint as a last-mile distribution moat for GLP-1 weight-loss and diabetes drugs — among the fastest-growing drug categories in pharmaceutical history. The thesis is that as GLP-1 prescriptions scale from millions to potentially tens of millions of patients, whoever owns the dispensing infrastructure wins a durable volume stream. At least one named Wall Street analyst has put a buy rating behind this angle.

The numbers, however, tell a complicated story. CVS reported $402.1B in revenue for FY2025 — up a healthy 7.8% year-over-year — but net margins are a threadbare 0.4%, translating to roughly $1.39 in diluted EPS. That margin profile reflects the structural squeeze hitting CVS simultaneously from multiple directions: PBM (pharmacy benefit manager) reform pressure in Washington, reimbursement rate compression, and the secular decline of front-of-store retail.

The bull case is straightforward: GLP-1 scripts are growing explosively and CVS's physical network, combined with its Caremark PBM and Aetna insurance arm, creates a vertically integrated funnel that pure-play pharmacies and mail-order competitors can't easily replicate. If GLP-1 volume scales as projected, CVS could see meaningful script count and fee-per-dispense tailwinds without proportional cost increases.

The bear case is equally concrete: CVS is a $402B revenue company earning 0.4% net margins with EPS barely above $1. Any GLP-1 upside is largely passed through to drug manufacturers (Novo Nordisk, Eli Lilly) and PBM contracts — not retained by the pharmacy. Meanwhile, regulatory risk around PBM practices is real and unresolved, and the stock has been a chronic underperformer. A single analyst's enthusiasm is not a consensus call.

The key watch items are Q2 GLP-1 script volume disclosures, any PBM legislation movement in Congress, and whether CVS can demonstrate margin improvement at the next earnings print. The GLP-1 narrative is real, but translating pharmacy traffic into bottom-line expansion for a near-zero margin business is the unproven leap.